Подписаться
Bishal Paudel
Bishal Paudel
University of Virginia, Department of Biomedical Engineering, UVA Comprehensive Cancer Center
Подтвержден адрес электронной почты в домене virginia.edu
Название
Процитировано
Процитировано
Год
Quantifying drug combination synergy along potency and efficacy axes
CT Meyer, DJ Wooten, BB Paudel, J Bauer, KN Hardeman, D Westover, ...
Cell systems 8 (2), 97-108. e16, 2019
1502019
An unbiased metric of antiproliferative drug effect in vitro
LA Harris, PL Frick, SP Garbett, KN Hardeman, BB Paudel, CF Lopez, ...
Nature methods 13 (6), 497-500, 2016
1102016
Dependence on glycolysis sensitizes BRAF-mutated melanomas for increased response to targeted BRAF inhibition
KN Hardeman, C Peng, BB Paudel, CT Meyer, T Luong, DR Tyson, ...
Scientific reports 7 (1), 42604, 2017
562017
A nonquiescent “idling” population state in drug-treated, BRAF-mutated melanoma
BB Paudel, LA Harris, KN Hardeman, AA Abugable, CE Hayford, ...
Biophysical journal 114 (6), 1499-1511, 2018
362018
Quantifying heterogeneity and dynamics of clonal fitness in response to perturbation
PL Frick, BB Paudel, DR Tyson, V Quaranta
Journal of cellular physiology 230 (7), 1403-1412, 2015
322015
Metabolic plasticity meets gene regulation
BB Paudel, V Quaranta
Proceedings of the National Academy of Sciences 116 (9), 3370-3372, 2019
272019
Drug-tolerant idling melanoma cells exhibit theory-predicted metabolic low-low phenotype
D Jia, BB Paudel, CE Hayford, KN Hardeman, H Levine, JN Onuchic, ...
Frontiers in Oncology 10, 1426, 2020
172020
An integrative gene expression and mathematical flux balance analysis identifies targetable redox vulnerabilities in melanoma cells
BB Paudel, JE Lewis, KN Hardeman, CE Hayford, CJ Robbins, ...
Cancer research 80 (20), 4565-4577, 2020
102020
Quantifying drug combination synergy along potency and efficacy axes. Cell Syst. 2019; 8: 97–108. e16
CT Meyer, DJ Wooten, BB Paudel, J Bauer, KN Hardeman, D Westover, ...
6
Disruption of redox balance enhances the effects of BRAF-inhibition in melanoma cells
BB Paudel, JE Lewis, KN Hardeman, CE Hayford, CJ Robbins, ...
bioRxiv, 818989, 2019
32019
Dynamics of drug response informs rational combination regimens
BB Paudel, V Quaranta
Science signaling 12 (595), eaax9742, 2019
32019
A heterogeneous drug tolerant persister state in BRAF-mutant melanoma is characterized by ion channel dysregulation and susceptibility to ferroptosis
CE Hayford, PE Stauffer, B Baleami, BB Paudel, DR Tyson, A Al’Khafaji, ...
bioRxiv, 2022.02. 03.479045, 2022
12022
Population modeling by examples III
Population Modeling Working Group
Proceedings of the Summer Simulation Multi-Conference, 1-12, 2017
12017
Uncovering the molecular basis for clinically relevant sphingolipidomic subtypes in acute myeloid leukemia
BB Paudel, SF Tan, J Ung, D Claxton, DJ Feith, TP Loughran, KA Janes
Cancer Research 84 (6_Supplement), 4947-4947, 2024
2024
Acute myeloid leukemia stratifies as 2 clinically relevant sphingolipidomic subtypes
BB Paudel, SF Tan, TE Fox, J Ung, U Golla, JJP Shaw, W Dunton, I Lee, ...
Blood Advances 8 (5), 1137-1142, 2024
2024
Proteome-wide copy-number estimation from transcriptomics
AJ Sweatt, CD Griffiths, BB Paudel, KA Janes
bioRxiv, 2023
2023
Nucleocytoplasmic transport of active HER2 causes fractional escape from the DCIS-like state
L Wang, BB Paudel, RA McKnight, KA Janes
Nature Communications 14 (1), 2110, 2023
2023
Divergentnucleocytoplasmic transport influences escape from HER2-activated DCIS-like state
L Wang, B Paudel, A McKnight, K Janes
Cancer Research 83 (7_Supplement), 2565-2565, 2023
2023
Therapeutic methods and compositions for treating cancer using braf and/or mek inhibitor combination therapy
L Audoly, BB Paudel, V Quaranta
US Patent App. 17/800,394, 2023
2023
Methods for evaluating therapeutic benefit of combination therapies
CT Meyer, V Quaranta, LA Harris, BB Paudel, DJ Wooten, L Audoly
US Patent App. 17/180,280, 2021
2021
В данный момент система не может выполнить эту операцию. Повторите попытку позднее.
Статьи 1–20